Barr, Par Settle With Valeant Over Epilepsy Drug

Law360, New York (October 15, 2007, 12:00 AM EDT) -- Barr Pharmaceuticals Inc. and Par Pharmaceutical Cos. Inc. have finalized a settlement with Valeant Pharmaceuticals North America over a generic version of Valeant’s epileptic seizure treatments Diastat and Diastat AcuDial.

On Monday, Barr said the settlement allows the company to launch a generic version of Valeant’s diazepam rectal gel products in September 2010, or “earlier in certain circumstances.” Barr will sell the generic product and split profits with Par.

The settlement puts to rest an ongoing civil suit between Xcel Pharmaceuticals, which has since been acquired...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.